In these trials, treatments with secukinumab and ixekizumab, anti-IL-17 monoclonal antibodies, and brodalumab, an IL-17RA receptor antagonist, indicate IL-17 inhibitors as superior in psoriasis efficacy compared to TNFα inhibitors and IL-12/IL-23 inhibitors with very few serious adverse events [37–43]. The gene discussed is TNF; the disease is psoriasis.